Time to complete:
Date of publication:
This is a recording of a live webinar that took place on 5 July 2021. This recording will be available to view until 5 April 2022.
Join us for this FREE live 90-minute webinar focusing on the managing type 2 diabetes in the primary care setting. The webinar will focus on managing type 2 diabetes as a bigger metabolic disorder and the guidelines and practicalities.
The vast majority of people with type 2 diabetes access their care largely or exclusively in primary care. There is good evidence that tight glycaemic control in the early decades of type 2 diabetes provides a 'legacy effect' of benefit in terms of microvascular and macrovascular complications which persists for life.
However, while lifestyle is a key factor in improving outcomes, engaging patients in positive lifestyle changes and medication adherence are ongoing challenges. In addition, primary care studies show clear evidence of clinical inertia, with long delays in intensification of treatment resulting in the patient living in a glucotoxic environment. However, to complicate matters, age and frailty may influence targets.
Advances in preventive treatments for glucose as well as blood pressure and cholesterol allow a real opportunity for primary care teams to have a major positive influence on long term outcomes – as long as they have the patient on board.
- Understand the rationale for gylcaemic control targets for patients with type 2 diabetes in primary care.
- Examine the evidence and best practice for personalised HbA1c targets dependent on age, frailty and co-morbidities.
- Learn about the use of consultation tools such as shared decision making to set aims and improve adherence to lifestyle goals and medication.
Dr Sarah Jarvis MBE, GP and Clinical Director of Patient.info.
Dr Sarah Jarvis MBE, GP and Clinical Director of Patient.info
Dr Sarah Davies, GPwSI in Diabetes and Diabetes UK Clinical Champion
This webinar is funded by:
This series of medical education webinars is sponsored by Boehringer Ingelheim and Lilly Diabetes Alliance (The Alliance). The Alliance had no influence over the agenda, programme development, content or selection of faculty. Editorial and content decisions were made solely by the RCGP and faculty chosen by RCGP.